Avacta Share Discussion Threads

[pwhite73] 22/10/2024 09:00

Rajraj b - "are you saying the Db pharmacology analyst have determined that AVA6000 was found to be unsafe and as such has failed its Phase1 trial?"

I have said nothing of the kind. Indeed I agree that AVA6000 is 100% safe and has no toxicity levels simply because it does not work. There is no warhead that releases DOX into the tumour or anywhere else for that matter.

What Avacta has reported is not enough to take the drug even to Phase 1b let alone Phase 2. This is what DB has reported. The failure is 100% around efficacy not safety.

[1347] 22/10/2024 08:57

No it hasn't, stop making stuff up. What they reported is not adequate to judge efficacy and is mostly subjective, no way can any comparison of efficacy be done with standard dox or a placebo from what they've done so far, only safety. Without a Phase 2 trial AVA6000 goes nowhere. Now when is that starting? When is the Phase 1 for AVA3996 starting? They had two main platforms, Precision and Affimers, neither have got very far after years of work, so they've gone back to the drawing board. Anyone with half a brain can see the situation, especially the DB analysts.

[rajraj b] 22/10/2024 08:43

Efficacy has also been reported in the phase 1 results by Avacta.

[rajraj b] 22/10/2024 08:42

Regarding your point 1, are you saying the Db pharmacology analyst have determined that AVA6000 was found to be unsafe and as such has failed its Phase1 trial? If so could you please explain to me where in any of the data Avacta have released or better still which data points DB have used to come to this conclusion. The reason I ask this is because I believe Avacta have said that minimal toxic side effects were recorded and they could not find a maximum tolerated dose. It just conflicts with what DB are saying, according to you.

[pwhite73] 22/10/2024 07:47

However I reiterate the company is now on the right path if it wants to raise the share price. Going back to square one with new pre-clinical drugs that use preCISION and rope in the dead horse Affimers is the only way to boost the share price.

At this early stage they can talk about partnerships with AI companies without having to prove damn thing.

[pwhite73] 22/10/2024 07:38

Divmad - "Excuse me? AV6k "quietly dropped Are we living in the same planet?"

Yes it has officially been dropped for the following reasons.

1. Deutsch Bank pharmacology analysts have confirmed the drug has failed Phase 1a.

2. A drug must prove efficacy and effectiveness at Phase 1 to be granted permission by the FDA to move into Phase 2.

3. Avacta does not have the money or will it find a partner to invest £20 million in a Phase 2 trial that has shown no efficacy or effectiveness at Phase 1a.

4. Of all the clinical trial stages Phase 2 has the highest failure rate. Only 18% of drugs make it past Phase 2. Nobody would risk a £20 million investment at Phase 2 when Phase 1a has failed.

5. Do you seriously think its a mere coincidence that the next generation of AVA drugs have been announced after the DB report on AVA6000?.

AVA6000 is finished and so is its sister drug AVA3996.

[1347] 21/10/2024 18:57

Divmad I don't have one.

nodoe Any new cancer treatment would be great, but Avacta don't have one, maybe they will one day but at best it's a long way down the line and other companies have better candidates than AVA6000 which thus far has not got past Phase 1 after over 3 years (and that's not counting the work Arisaph did).

[nodoe] 21/10/2024 18:28

1347...You're right, I think it will go less than 10p when the world realises that they would prefer to let cancer suffers die in pain rather than extend life with no pain..

[divmad] 21/10/2024 18:21

What's your stop loss point, 1347?

[1347] 21/10/2024 18:00

Tomz, thanks. Yes that's how they work, a couple of 'positive' RNS, or at least enough to provide an excuse for the MMs and Brokers to raise the price and offload the shares at a price above what they know the newly issued shares will be when they hit the market shortly afterwards. Rinse & repeat.

If you think about it Avacta have gone all the way back from the worlds best test (allegedly) to a ground breaking new delivery method for oncology treatment (allegedly) and now sit at or near square one with a new set of pre-clinical candidates. Rinse & repeat.

I'm absolutely fine if others see it differently but Mr Market certainly doesn't.

[pwhite73] 21/10/2024 17:28

bbd2 - "Tempus will now have the opportunity to have a good old nose at the business with that collaboration."

There is no collaboration. Tempus has a dataset of information in a beta set up they have given access to Avacta and a million other companies.



9/12/2024

Tempus Launches Beta Version of olivia, its AI-enabled Personal Health Concierge App for Patients

CHICAGO --(BUSINESS WIRE)--Sep. 12, 2024-- Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the beta launch of a patient-facing app, olivia , an AI-enabled personal health concierge to empower individuals.

9/26/2024

Tempus Announces Expansion of Collaboration with Takeda to Leverage Multimodal Real-World Datasets and Biological Model Systems in Oncology Research and Development

CHICAGO --(BUSINESS WIRE)--Sep. 26, 2024-- Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announces an expansion to its collaboration with Takeda (TSE:4502/NYSE:TAK) that takes a data-first approach to research"

Its like you taking out a membership at your local library giving you access to thousands of books, periodicals, newspapers and magazines. Nothing more than that.

[bbd2] 21/10/2024 16:50

Tom- what after hours RNS?

[tomzimerman] 21/10/2024 16:39

Maybe you owe 1347 an apology, he clearly wasn't a disrupter and just ahead of the game or imo knows the game. Rns after close today smells of desperation and shenanigans after a positive rns first thing used to pump retail into adding Ouch

[fieldhouse] 21/10/2024 15:49

Interesting times

[bbd2] 21/10/2024 15:49

Tempus will now have the opportunity to have a good old nose at the business with that collaboration. Interesting times.

[bbd2] 21/10/2024 15:46

Well that was an interesting last half hour of trading to end nicely up. Tomorrow’s opening rush will be fun to watch. Who would risk being short when the diagnostics sale RNS lands.

[fieldhouse] 21/10/2024 15:44

Not gone your way today!,
TempusAi very interesting company .Valued at over 7 billion dollars.
Could be a way for Avacta to be taken over !
Changing to a technology company and licensing their tec.
Could be a very bright future .

[1347] 21/10/2024 15:34

Not going anywhere, I am perfectly entitled to post my opinion on this company, it's not your fiefdom. If you and other rampers don't like it, well that's just tough. I suggest you hit the filter button and stay in your echo chamber.

However I do suggest you do some better research, failing that a look at the share price chart gives a simpler view of the trajectory, even you should be able to figure out where that's gone over the last year or so and where this is heading.

[dudishes] 21/10/2024 15:33

US:TEM, mkt cap $7.6Bn.

Fact or fiction?

DB not changed their stance, 40p.

[dudishes] 21/10/2024 15:30

wiseacre, it is!

[wiseacre] 21/10/2024 15:25

looks a good short to me

[fieldhouse] 21/10/2024 15:19

1347,
What on earth are you doing writing on this bb.
You are not invested and are clearly a disrupter.
For goodness sake,get a life and do all of us a favour and stop pontificating .

[1347] 21/10/2024 15:13

As I and others have pointed out, recent powder puff RNS announcements were merely desiged to help forward sell the next pay day loan/death spiral finance conversion. Still £30 m to go and ever and ever lower prices. Heading for 10p?

London - Oct. 21, 2024 - Avacta Therapeutics (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs, today announces it has issued and allotted a total of 5,930,659 new ordinary shares of 10 pence each in the Company ("New Ordinary Shares").

The New Ordinary Shares are being issued in settlement of the quarterly principal of £2.55 million and interest repayment of £0.54 million in respect of the Company's unsecured convertible bond.

After settlement of the quarterly repayment, the principal remaining under the convertible bond will be reduced by £2.55 million to £30.60 million.

[amanitaangelicus] 21/10/2024 08:53

I never, ever like delays on Aim. This is true of waiting for oil drilling results, pharma Phase data. I wonder if the delay is linked dotting the I's and crossing the t's on a farm in deal on AVA6k.Be interesting to see too just what kind of deal can be struck, if any deal.Cost of development v returns. Basic EBITDA stuff. Not a sniff from the big boys ,who I guess are digging in a different hole. ie gene editing etc. AI will undoubtedly dominate this protein structure stuff going fwd. GL.